Checking heart failure patients for a protein-related heart condition
Tests a bone-scan method to find transthyretin amyloidosis in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT05577819
- Record updated
- 1 September 2026
- Original description
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.Read full original descriptionShow less
Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Inclusion: Patients with a confirmed diagnosis of HFpEF; Age ≥65 years old.
Exclusion: Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary); End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR <15mL/min); no history of HFrEF (LVEF<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc; Negative 99mTc-pyrophosphate scan within a year; Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan; Known diagnosis of amyloidosis.